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ABSTRACT
Purpose This study reports on the long-term surgical
outcomes after the insertion of porous Medpor orbital
implants into anophthalmic sockets.
Methods A retrospective chart review of 314 eyes from
314 patients who underwent evisceration, enucleation
and secondary procedures using Medpor orbital implants
was completed focusing on implant-associated
complications and their corrective methods as surgical
outcomes.
Results The mean follow-up was 50 months (range
6e107 months). The most common complication was
blepharoptosis (n¼33, 10.5%). Other postoperative
complications were exposure (n¼14, 4.5%) and implant
infection (n¼3, 1%). The complications were
successfully managed by surgical repair and/or
conservative care.
Conclusion Using Medpor resulted in similar surgical
outcomes, in terms of the types and frequencies of
complications, as other kinds of porous orbital implants.
Medpor (Porex Surgical, Inc, College Park, Georgia,
USA) is a porous form of polyethylene that is now
widely used with hydroxyapatite to compensate for
the loss of volume in an anophthalmic socket after
enucleation or evisceration. In addition to its use in
anopthalmic socket surgery, Medpor is commonly
used in craniofacial reconstruction surgery. Because
the average pore diameter of Medpor is greater than
150 mm, which is above the standard limit (100 mm),
this material allows the ingrowth of host orbital
vasculature and soft tissue, which integrates the
implant with the host’s body. Medpor is a ﬁrm
material that is easily manufactured by heating
small polyethylene spheres.
1e3
Tissue ingrowth through the pores allows for
biointegration, which reduces the risk of extrusion
and exposure. Furthermore, Medpor reduces the
infection rate because the invasion of vascular
structures through the pores of the orbital implant
enables an immune response to infection, and
antibiotics can also be delivered by systemic
administration to the orbital implant.
4 5 However,
it is possible for an abscess to develop in the
internal lacuna of Medpor, and connective tissue
may erode due to the rough surface.
67Therefore,
the most serious complications associated with
integrated orbital implants after evisceration or
enucleation are still exposure and infection.
Although efforts have been made to reduce these
complications, the reported rates vary from 0% to
21%.
8e15
However, few studies have reported on the
general postoperative complications after Medpor
implantation in a large cohort. Alwitry et al
16
reported long-term follow-up results (6 years) of
porous polyethylene spherical implants after
enucleation and evisceration in 106 patients, but
this report placed emphasis on the superiority of
operative techniques such as evisceration or
enucleation, which is insufﬁcient for a general
assessment of the long-term surgical outcomes of
Medpor orbital implants.
We report here on the long-term surgical
outcomes of 314 patients who underwent enucle-
ation, evisceration, or secondary orbital implanta-
tion with a porous polyethylene (Medpor) orbital
implant at our hospital, and compare these
outcomes with those of previously published
research.
PATIENTS AND METHODS
We performed a retrospective chart review of 314
patients who underwent primary placement of
a porous polyethylene orbital implant after
enucleation, evisceration, or secondary implanta-
tion by an oculoplastic surgeon (SWY) at Seoul St
Mary’s Hospital between 1998 and 2008. All
patients provided fully informed written consent
for surgery, and all patients were followed up for
more than 6 months after surgery. Patient demo-
graphics, indications for the procedure, type of
procedure, size of the implant placed, duration of
follow-up, any complications encountered and
patient management procedures were recorded.
Enucleation was only performed for patients in
whom evisceration was contraindicated; for
example, if there was suspicion of an intraocular
tumour on clinical examination or imaging study or
those cases in whom it was too difﬁcult to perform
an evisceration due to severe phthisis or severe
retrobulbar damage.
A 3608 peritomy was performed at the limbus for
enucleation, and the four quadrants were bluntly
dissected to release the conjunctiva and Tenon’s
capsule from the globe. The four rectus muscles
were identiﬁed and isolated using muscle hooks.
The muscles were cleaned of tendon and were
secured with locked 5-0 polyglactin (Vicryl; Ethicon
Inc., Johnson & Johnson Co., Somerville, New
Jersey, USA) sutures before being detached from the
globe. The dissection continued posteriorly, and the
superior and inferior oblique muscles were cut. The
optic nerve was transected with blunt curved scis-
sors. The loose globe was removed, and haemo-
stasis was secured with monopolar diathermy and
pressure application. A sizing ball was used to
assess the residual intraconal volume, and implant
size was chosen to allow tension-free closure of the
anterior ocular tissue. A porous polyethylene
(Medpor) implant was left within its sterile
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Clinical sciencepackage, and allowed to bathe fully in 10 ml saline with 80 mg
gentamicin sulphate (Gentamicin; Kukje Pharm, Seoul, Korea)
for 30 min. The implant was inserted intraconally, and the
rectus muscles were attached directly to the implant. Tenon’s
capsule and conjunctiva were closed in layers with 6-0 poly-
glactin sutures (Vicryl; Ethicon Inc.).
A 3608 peritomy was performed for evisceration, and an
incision was made circumferentially in the sclera approximately
1e2 mm from the limbus. An evisceration spoon was used to
separate the uveal tissue from the scleral shell, and the globe
contents were delivered. The inside of the globe was then
cleaned and debrided with a gauze swab. Anterior relaxing
incisions were made in the sclera, avoiding the rectus muscles.
Additional relaxing incisions were made at the equator level
circumferentially. An appropriately sized Medpor implant was
inserted using the same method as for enucleation. The implant
was inserted, and the scleral shell was closed with 5-0 poly-
glactin (Vicryl; Ethicon Inc.) interrupted sutures using the
wrapping method. Tenon’s capsule and conjunctiva were closed
in layers with 6-0 polyglactin (Vicryl; Ethicon Inc.) sutures,
respectively.
Horizontal conjunctival incisions were made during secondary
implantation, and any pseudocapsule was dissected and
removed. An appropriately sized Medpor orbital implant was
inserted, and the last step consisted of meticulously closing the
anterior and posterior Tenon’s capsule and conjunctiva as sepa-
rate layers with 6-0 polyglactin (Vicryl; Ethicon Inc.) sutures.
After all the procedures were done, a conformer was inserted,
and antibiotic ointment was placed on the ocular surface to
prevent dehiscence and infection of the initial wound. The
conformer was maintained for 4 weeks. Further follow-up visits
were scheduled at 2, 4, 6 and 8 weeks, 6 and 12 months, and
every 12 months thereafter.
The postoperative complications found during the follow-up
period were classiﬁed into orbital implant, conjunctiva and
lid abnormality groups, and we performed surgical or medical
management according to the types and severity of the
postoperative complications.
RESULTS
A total of 314 cases was identiﬁed, and the mean follow-up
period was 50 months (range 6e107 months). Forty-three
patients (13.7%) underwent enucleation, 229 (72.9%) under-
went evisceration, and 42 (13.4%) underwent secondary orbital
implantation (table 1). Trauma was the most common original
cause of the need for enucleation or evisceration, accounting for
173 patients (55.2%). Glaucoma made up a large portion of the
original causes for performing an evisceration rather than other
procedures (14.8% vs 2.3% and 14.8% vs 9.5%). Infection or
inﬂammation was a more common reason for performing
enucleation or secondary orbital implantation instead of evis-
ceration. Enucleation was performed in cases with a suspicious
or conﬁrmed ocular tumour (table 2).
The orbital implant size ranged from 14 to 22 mm, with the
most common being an 18-mm implant (52.2%). The most
common type of implant used in surgery was an orbital sphere
type, the rest being either the Medpor smooth surface tunnel
(SST) implant or the Medpor multipurpose conical orbital
implant (MCOI) (table 3).
The most common postoperative complication was blephar-
optosis (10.5%), followed by eye discharge (6.4%), implant
exposure (4.5%), conjunctival contracture (4.5%), ectropion
(3.5%) and implant infection (1%) in a total of 314 patients. The
overall postoperative complication incidences were 72.1% (31/
43) in patients who received enucleation, 27.1% (62/229) in
patients who received evisceration and 59.5% (25/42) in patients
who received secondary orbital implantation. The most
common postoperative complication was blepharoptosis in all
three groups (table 4).
All three patients with an implant infection underwent
implant exchange. Staphylococcus aureus was cultured in two
cases, and Streptococcus epidermidis was cultured in one case
(table 5). All 14 cases of implant exposure were signiﬁcant in
size, which required operative intervention with an alloderm
graft or sclera. Four patients (28.6%) who received enucleation,
eight patients (57.1%) who received evisceration and two
patients (14.3%) who received secondary orbital implantation
were included in these 14 cases. After this surgical intervention,
two cases of implant exposure recurred. One of these cases
underwent an implant exchange, and the other case underwent
implant removal (table 6). The four cases of giant papillary
conjunctivitis were recovered with conservative care, and
removal was performed in two cases of conjunctival cyst and
granuloma. Nine cases of fornix contracture (9/14, 64.3%)
Table 1 Patient demographics
Characteristic
Enucleation
(N[43)
Evisceration
(N[229)
Secondary orbital
implantation (N[42)
Total
(N[314)
Age, years (range) 46.81 (2e78) 51.54 (2e87) 47.25 (1e77) 50.35 (1e87)
Gender (M:F) 19:24 112:117 20:22 151:163
Follow-up, months (range) 44 (6e92) 46 (6e107) 58 (6e87) 50 (6e107)
N, number of patients.
Table 2 Original causes for anophthalmic surgery
Cause Enucleation (N[43) Evisceration (N[229)
Secondary orbital
implantation (N[42)
Total
(N[314)
Trauma (%) 21 (48.8%) 132 (57.6%) 20 (47.6%) 173 (55.2%)
Glaucoma (%) 1 (2.3%) 34 (14.8%) 4 (9.5%) 39 (12.4%)
Corneal ulcer (%) 3 (7.0%) 29 (12.7%) 4 (9.5%) 36 (11.5%)
Ocular inﬂammation/infection (%) 9 (21.0%) 14 (6.1%) 6 (14.4%) 29 (9.2%)
Tumours (%) 8 (18.6%) 0 (0%) 4 (9.5%) 12 (3.8%)
Others (%) 1 (2.3%) 20 (8.8%) 4 (9.5%) 25 (7.9%)
N, number of patients.
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Clinical sciencereceived reconstruction with oral mucosa and dermis, and ﬁve
cases (5/14, 35.7%) received reconstruction with alloderm
(Surederm; Hans Biomed Co, Seoul, Korea). Three cases (3/4,
75.0%) of wound dehiscence, which were small and caused by an
inapproximated conjunctival suture, required only conservative
management, but one case (1/4, 25.0%) received an additional
suture. Most of the complications associated with lid problems
(39/54, 72.2%) required operative management. For the
blepharoptosis (n¼33) and dermatochalasis cases (n¼3), 18
patients (18/36, 50.0%) received a blepharoplasty, 10 (10/36,
27.8%) received a levator resection and three (3/36, 8.3%)
received levator advancement. Three patients who had a deep
upper lid sulcus received silastic sheet insertion on the superior
orbital wall via the skin incision. Three patients who had lower
lid entropion received lower lid retractor re-insertion, and two
patients received Quickert suture. Ocular pain or eye discharge
was treated with conservative care, and these patients recovered.
We did not routinely use a motility coupling post (MCP)
because most patients who had undergone anophthalmic
surgery and obtained a sufﬁcient conjunctival fold showed good
movement without a MCP. Only 32 patients received a MCP
insertion, ﬁve needed a position recorrection, and two under-
went re-insertion due to failure. No infection was observed in
the patients who received a MCP insertion (table 7).
DISCUSSION
Polyethylene is a high-density, straight-chain hydrocarbon
formed by polymerisation of ethylene molecules under high
temperature and pressure. Medpor is a polyporous form
(150e400 mm) of polyethylene that is manufactured by heating
and compacting polyethylene granules into spherical shapes of
different size. This porous character enables ﬁbrovascular
proliferation of orbital tissue, reduces the risk of migration,
exposure and extrusion, and minimises the risk of infection. This
material is also non-toxic, non-allergenic and highly biocom-
patible. It is not brittle, thus allowing muscles to be sutured
directly to it with no need for sclera.
1e4 Many studies have
reported favourable surgical outcomes after Medpor orbital
implantation.
17e22
Medpor has a rough surface, which tends to cause erosion of
Tenon’s capsule and conjunctiva and eventually implant expo-
sure. To compensate for this defect, other types of Medpor have
been introduced. Medpor SST is a further reﬁnement of the
original polyporous polyethylene (Medpor). It has a smooth,
porous anterior surface, which helps minimise late-implant
exposures, and the suture tunnels allow for easy attachment of
the rectus muscle without the use of an implant wrap. Medpor
MCOI is cone-shaped, which makes it possible to provide
additional volume in the orbit with a similar diameter implant.
Medpor MCOI has more utility in patients with severe phthisis
bulbi. Medpor is currently a very popular polyporous orbital
implant material. The other orbital implant materials include
hydroxyapatite and aluminum oxide.
However, unlike hydroxyapatite implants, only relatively
small case series have been published on the exposure and
complication rates of Medpor orbital implants. Karcioglu et al
23
reported eight cases of conjunctival dehiscence exposure, ﬁve
cases of fornix contracture and three cases of inappropriate
volume replacement in 37 patients who underwent enucleation
and Medpor orbital implantation due to retinoblastoma. Cheng
et al
24 reported that implant exposure occurred in up to one-
third of patients who received Medpor orbital implantation over
a 2-year follow-up period, and this was particularly common
after MCP insertion. Shoamanesh et al
25 reported postoperative
complications in 32 patients who had received Medpor implants
with a 14-year follow-up period. Baek
17 reported ﬁve cases of
implant exposure and four cases of superior sulcus deformity in
36 patients after evisceration, enucleation, or secondary orbital
implantation during 2 years of follow-up. We studied the overall
postoperative outcomes in 314 patients over 10 years of
follow-up.
Our study showed only a 1% (3/314) incidence rate of Medpor
orbital implant infection, and these three cases required an
Table 3 Distribution of Medpor type check
Size, mm Orbital sphere SST sphere MCOI Total (%)
14 4 ee 4 (1.3)
16 7 0 1 8 (2.5)
18 139 8 17 164 (52.2)
20 134 3 0 137 (43.7)
22 1 0 e 1 (0.3)
Total 285 11 18 314
SST, smooth surface tunnel; MCOI, multipurpose conical orbital implant.
Table 4 Postoperative complications
Complications
Enucleation
(N[43)
Evisceration
(N[229)
Secondary
orbital
implantation
(N[42)
Total
(%)
Implants Infection 0 3 0 3 (1.0)
Exposure 4 8 2 14 (4.5)
Conjunctiva Giant papillary
conjunctivitis
0 3 1 4 (1.3)
Conjunctival
cyst/granuloma
0 1 1 2 (0.6)
Fornix
contracture
6 7 1 14 (4.5)
Wound
dehiscence
1 2 1 4 (1.3)
Eyelid Blepharoptosis 9 18 6 33 (10.5)
Dermatochalasis 0 2 1 3 (1.0)
Deep upper lid
sulcus
1 4 2 7 (2.2)
Entropion 4 5 2 11 (3.5)
Others Pain/discomfort
(>6 weeks)
1 1 1 3 (1.0)
Discharge
(>6 weeks)
5 8 7 20 (6.4)
N, number of patients.
Table 5 Postoperative orbital implant infections
No
Gender/age
(years)
Preoperative
diagnosis
Type of
surgery
Size of
implant (mm)
Complication-free
follow-up period (months)
MCP
insertion
Cultured
microorganism
1 M/39 Trauma Evisceration 20 46 No S aureus
2 M/44 Trauma Evisceration 18 1 No S epidermidis
3 M/43 Phthisis bulbi Evisceration 18 59 No S aureus
MCP, motility coupling post.
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Clinical scienceimplant exchange. This rate is similar to the infection rate of the
hydroxyapatite orbital implant, which ranges from 0% to
1.5%.
26 27 Postoperative implant infection using Medpor is rare,
limited to only a few case reports,
52 82 9probably because
Medpor has a hydrophobic and negatively charged surface that
acts as a protective envelope to inhibit the adherence of
bacteria.
28
In the present study, implant exposure occurred in 9.3% of
patients who underwent enucleation and in 3.5% of patients who
underwent evisceration. Alwitry et al
16 reported the long-term
follow-up surgical outcomes (6 years) of 106 patients who
underwent spherical Medpor implantation, and reported that the
implant exposure rate was 6.3% (5/80) for patients who under-
went enucleation and 53.8% (14/26) for patients who underwent
evisceration. The original reason for the surgery was different
between the study of Alwitry et al
16 and our study. The most
common cause of anophthalmic surgery was trauma in both
studies, but its frequency was different: approximately 30% in our
study and up to 50% in the study by Alwitry et al.
16 In both
studies, the surrounding tissue around the eyeball was damaged by
t r a u m a ,a n dt h ed e g r e eo fd a m a g ea f f e c t e dr e c o v e r yr a t ea n dt h e
ﬁnal surgical outcome. Therefore, a simple comparison of inci-
dence rates between the two studies has no meaning. In addition,
we included data on patients who received Medpor MCOI and
Medpor SST, not just the spherical Medpor, which may have
inﬂuenced our results, whereas the study by Alwitry et al
16 only
included data on patients who received the spherical Medpor.
The results showed similar postoperative complication rates,
except the rate of fornix contracture between the patients who
had received enucleation (6/43, 14.0%) and secondary orbital
implantation (1/42, 2.4%). This result was caused by the fact
that secondary orbital implantation was mostly considered
when an unﬁt artiﬁcial eye was detected.
Yoon et al
26 reported that the rate of orbital implant exposure
in 802 patients who received hydroxyapatite orbital implanta-
tion with a 15-year follow-up was 2.1%. Shoamanesh et al
25
Table 6 Postoperative orbital implant exposure
No
Gender/age
(years)
Preoperative
diagnosis
Type of
previous
surgery
Size of
implant
(mm)
MCP
insertion
Complication-free
follow-up period
(months)
Recurrence after
management using
sclera or alloderm graft
1 M/66 Trauma Enucleation 20 None 20 None
2 M/46 Tumour Enucleation 18 Yes 27 None
3 F/60 Ocular infection Enucleation 18 None 30 None
4 M/49 Trauma Enucleation 20 None 47 None
5 F/38 Trauma Evisceration 20 None 61 None
6 M/55 Trauma Evisceration 20 None 14 Yes (implant exchange)
7 F/44 Trauma Evisceration 18 None 26 None
8 M/43 Trauma Evisceration 18 None 38 None
9 M/75 Phthisis bulbi Evisceration 20 None 55 None
10 F/68 Glaucoma Evisceration 20 None 29 None
11 F/73 Phthisis bulbi Evisceration 20 None 35 None
12 M/39 Trauma Evisceration 20 None 24 None
13 F/50 Glaucoma Secondary orbital implantation 18 None 18 Yes (implant removal)
14 M/59 Trauma Secondary orbital implantation 18 None 38 None
MCP, motility coupling post.
Table 7 Patients with a MCP
Type of operation No of patients
Enucleation 14 (3: recorrection, 2:
succeeded after a failure)
Evisceration 13 (2: recorrection)
Secondary orbital implantation 5
Total 32
MCP, motility coupling post.
Table 8 Summary of the major studies on porous orbital implants
Complications Material
Our study Alwitry et al
16 Shoamamesh et al
25 Blaydon et al
18 Yoon et al
26
(N[314) (N[106) (N[32) (N[136) (N[802)
Porous
polyethylene
Porous
polyethylene
Porous
polyethylene
Porous
polyethylene Hydroxyapatite
Implants Infection 3 0
Exposure 14 19 2 5 55
Conjunctiva Giant papillary conjunctivitis 4 1
Conjunctival cyst/granuloma 1 2 2 6 2
Fornix contracture 14 3
Wound dehiscence 4 1 28
Eyelid Blepharoptosis 33 9
Dermatochalasis 3
Deep upper lid sulcus 7
Entropion 11
Others Pain/discomfort (>6 weeks) 3 1
Discharge (>6 weeks) 20 4 38
N, number of patients.
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Clinical sciencefound that the rate of exposure was 6% for 432 patients who
underwent hydroxyapatite orbital implantation and 6.25% for 32
patients who underwent Medpor orbital implantation. Baek
17
reported a rate of exposure of 13% for 36 eyes that underwent
Medpor orbital implantation; however, all 36 eyes successfully
recovered with a dermograft. Custer and Trinkaus
30 reported that
the exposure rates were similar between hydroxyapatite (5.1%)
and Medpor (4.2%) when patients with retinoblastoma were
omitted from the pooled data in a meta-analysis of porous orbital
implant studies. These reports show that surgical outcomes vary
according to factors such as operator technique and the status of
the conjunctiva around the operation site. More studies may be
needed to determine conclusively whether hydroxyapatite or
Medpor is superior, because few studies have focused on patients
who received Medpor orbital implants.
Other postoperative complications may also occur, including
conjunctival abnormalities and lid problems. Yoon et al
26
reported that conjunctival cysts and conjunctival wound
dehiscence occurred in 0.2% and 3.5% of patients who received
hydroxyapatite orbital implantation, respectively, but they did
not receive pegging. No marked differences were observed
between the study of Yoon et al
26 and our study, which showed
rates of 0.6% and 1.3% for conjunctival cysts and conjunctival
wound dehiscence, respectively. Shoamanesh et al
25 found that
blepharoptosis occurred in 20.1% of patients who underwent
Medpor orbital implantation, and this was the most common
postoperative complication. Our study showed similar results;
blepharoptosis was the most common postoperative problem,
and its incidence rate was 10.5%. However, most cases of
blepharoptosis successfully recovered after a blepharoplasty or
other corrective operation (table 8).
MCP insertion was performed in 10.2% of the patients at our
institute, which is a relatively low rate, and most underwent
this procedure before 2002. MCP has been used to improve
artiﬁcial eyes, but it may increase the infection rate of an orbital
implant.
26 Furthermore, unskilled insertion of an MCP requires
repositioning or removal and re-insertion.
31 Therefore, we do not
typically perform MCP insertion if the motility of an artiﬁcial
eye is satisfactory and the patient does not wish to do it.
In summary, we report a large case series of patients
implanted with porous polyethylene orbital implants with an
extended follow-up. We highlighted the previously undocu-
mented general postoperative complications after Medpor
orbital implantation during long-term follow-up, and no marked
differences in the complications between hydroxyapatite and
Medpor were observed. We also successfully resolved the post-
operative complications associated with Medpor. Therefore, we
suggest that Medpor produces tolerable surgical outcomes as an
orbital implant because of lower material cost, convenience of
the operative procedure and other advantages.
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